Kyowa Kirin Data Shows Mogamulizumab Boosts Survival in Rare Blood Cancers — Kyowa Kirin Co., Ltd.

Event summary

Kyowa Kirin presented two indirect treatment comparison (ITC) analyses at the World Congress of Cutaneous Lymphoma 2026, showing mogamulizumab improved survival outcomes in relapsed or refractory mycosis fungoides (MF) and Sézary syndrome (SS).
Median overall survival (OS) was not reached for mogamulizumab patients compared to 31.0 months for vorinostat in Australia and 17.0 months for standard of care in Denmark.
Mogamulizumab reduced the risk of death by 52% versus vorinostat (HR: 0.48) in Australia and by 62% versus standard of care (HR: 0.38) in Denmark.

The big picture

Kyowa Kirin's new analyses address critical evidence gaps in cutaneous T-cell lymphoma (CTCL), a rare and difficult-to-treat blood cancer. The findings come as clinical trials increasingly integrate real-world data to demonstrate long-term outcomes, particularly for therapies like mogamulizumab where direct survival comparisons have been limited. This strategic move could bolster Kyowa Kirin's position in the hematologic malignancies space, especially as demand grows for personalized treatments in rare diseases.

What we're watching

Regulatory Approvals: Whether these findings will accelerate regulatory approvals in countries where mogamulizumab access is currently limited.
Market Penetration: The pace at which Kyowa Kirin can expand mogamulizumab's use in relapsed or refractory MF and SS patients globally.
Competitive Dynamics: How competing therapies will respond to these long-term survival data, potentially influencing treatment paradigms for CTCL.